Diligence memo · auto-generated · as of July 2, 2026
Arpeggio Biosciences, Inc.
Arpeggio Biosciences, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Arpeggio Biosciences, Inc. operates in Biotech / Pharma, based in BOULDER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Arpeggio Biosciences, Inc. has raised $46M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2022-08-03.
Most recent recorded round closed around 2025-11-12.
Valuation (modeled)modeled
Provath models Arpeggio Biosciences, Inc. at approximately $81M (range $41M–$111M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series B Biotech / Pharma companies in 2025–2027 (9 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 8 mo ago; this sector typically re-raises about every 15 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 5.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 87% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 67% of those peers.
Closest niche peers: Inductive Bio, Inc., Wheeler Bio, Inc., Abrexa Pharmaceuticals, Inc., Puna Bio Corp, Vinci Pharmaceuticals, Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.